// App-Quantinova.ai

EPCO-10 : SYSTEMS BIOLOGY-BASED THERAPEUTIC PREDICTIONS WITH GBMSYGNAL AND CLINICAL CORRELATES IN THE REAL-WORLD LONGITUDINAL OUTCOMES REGISTRY XCELSIOR

Researchers

Presenter

  • Timothy Stuhlmiller

Principal Investigators

  • Serdar Turkarslan

  • Julie Friedland

  • Mark Shapiro

  • Santosh Kesari

  • Anoop Patel

  • Nitin Baliga

Medical Centers

  • xCures, Holly Springs, NC, USA

  • University of Washington, Seattle, WA, USA

  • Saint John’s Cancer Institute at Providence St. John’s Health Center, Santa Monica, CA, Santa Monica, CA, USA

  • Institute for Systems Biology, Seattle, WA, USA

  • xCures, Philadelphia, PA, USA

  • xCures, San Francisco, CA, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Pembrolizumab

  • Valproic Acid

  • Valproate

  • Panobinostat

  • Tocilizumab

  • Bevacizumab

  • Palbociclib

  • Pemetrexed

  • Celecoxib

  • ALT-210

  • Alpelisib

  • Metformin Hydrochloride

  • Lomustine

  • Nilotinib

  • Selinexor

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT03793088

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved